Market Cap
$48.4M
TIL
Instil Bio, Inc.
$7.19 ▼ -0.62%
Prev close $7.24Market cap$48.4M
12-mo target$7.00 (-2.6%)
Biotech & Drug Discovery
Snapshot
The big-picture read on TIL right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
19 funds
Inst. Value
$6.5M
Inst. Activity
1 buys / 2 sells
Social Sentiment
67° Warm
SEC Reports
6
Press Releases
1
Price chart 30d -6.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 13, 2026 SEC Aug 13, 2026 SEC
Instil Bio reported Q2 2026 GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, driven by sharply
PRESS-RELEASE — Impact 4/10
Instil Bio reported Q2 2026 results with a GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, dri
8-K — Impact 4/10
Aug 13, 2026 earnings
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
177,423 shares ($1.4M)
Jun 30, 2026 Inst.
MORGAN STANLEY — TRIM
11,934 shares ($91.8K)
Jun 11, 2026 Insider
Binder Gwendolyn was granted 6,500 shares
Director
Jun 11, 2026 Insider
Gibson Neil W was granted 0 shares
Director
Jun 11, 2026 Insider
Matcham George was granted 6,500 shares
Director
Analyst ratings buy % -5.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jan 7, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Sep 11, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 27, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 15, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 5, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 2, 2025 | JMP Securities | REITERATE | Market Perform | 53% |
| May 23, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 22, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Mar 5, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Feb 13, 2025 | JMP Securities | REITERATE | Market Perform | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 3 | 2 | 0 | 0 | 71% | |
| Aug 1, 2026 | 2 | 3 | 2 | 0 | 0 | 71% | |
| Jul 1, 2026 | 2 | 3 | 2 | 0 | 0 | 71% | |
| Jun 1, 2026 | 2 | 3 | 2 | 0 | 0 | 71% | |
| May 1, 2026 | 2 | 3 | 2 | 0 | 0 | 71% | |
| Apr 1, 2026 | 2 | 3 | 2 | 0 | 0 | 71% | |
| Mar 1, 2026 | 2 | 3 | 3 | 0 | 0 | 63% | |
| Feb 1, 2026 | 2 | 3 | 3 | 0 | 0 | 63% |
Price targets
Where 1 covering analysts think TIL trades over the next 12 months.
$7.00 -2.6% upside Hold
Current$7.19 Low$7.00 Median$7.00 High$7.00 1 analysts
$7.00$7.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood -16.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 6 neutral · avg impact 3.7/10.Plus 1 press releases.
NEUTRALPRESS-RELEASE4/10
Instil Bio reported Q2 2026 GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025
Aug 13, 2026
NEUTRAL8-K4/10
Instil Bio reported Q2 2026 results with a GAAP net loss of $0.63 per share, narrowing from a $3.24
Aug 13, 2026
NEUTRAL8-K4/10
Instil Bio reported Q1 2026 GAAP EPS of -$0.62, a slight miss vs consensus -$0.59, but as a pre-reve
May 15, 2026
NEUTRALPRESS-RELEASE4/10
Instil Bio reported Q1 2026 GAAP EPS of -$0.62, beating the -$0.59 consensus by 5.1% (a beat), with
May 15, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 13, 2026
earnings
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 11, 2026
earnings_calendar
TIL Q2 2026 Earnings Scheduled — 2026-08-11
May 15, 2026
earnings
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
earnings_calendar
TIL Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
TIL Q1 2026 Earnings Scheduled — 2026-05-11
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.17 | $-0.17–$-0.17 | 91.5% | +0.0% | 1↑ 0↓ | $0.0B | 1 |
| Next Q | $-0.04 | $-0.04–$-0.04 | 96.7% | +0.0% | 1↑ 0↓ | $0.0B | 1 |
| Current FY | $-1.17 | $-1.17–$-1.17 | 89.1% | +0.0% | 1↑ 0↓ | $0.0B | 1 |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.170 | — |
| 7d ago | $-0.170 | — |
| 30d ago | $-0.170 | — |
| 60d ago | $-0.330 | +0.160 |
| 90d ago | $-0.330 | +0.160 |
Institutional ownership
Which big funds own TIL (from quarterly 13F filings) and who is adding or trimming.
19 institutional holders with $6.5M total value (849,746 shares) as of 2026-Q2. Top holders: UBS, VANGUARD, MILLENNIUM. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| UBS Group AG | 177,423 | $1.4M | 20.9% | DOUBLED +2681.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 163,738 | $1.3M | 19.3% | — |
| MILLENNIUM MANAGEMENT LLC | 134,575 | $1.0M | 15.8% | TRIM -45.2% |
| BlackRock, Inc. | 55,504 | $426.8K | 6.5% | — |
| RENAISSANCE TECHNOLOGIES LLC | 50,300 | $386.8K | 5.9% | TRIM -32.7% |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 50,000 | $385.0K | 5.9% | — |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 43,051 | $331.1K | 5.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 42,234 | $324.9K | 5.0% | — |
| LPL Financial LLC | 32,075 | $246.7K | 3.8% | — |
| CITADEL ADVISORS LLC | 30,639 | $235.6K | 3.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| UBS Group AG | DOUBLED | 6,378 | 177,423 | +2681.8% | $1.4M |
| MORGAN STANLEY | TRIM | 19,821 | 11,934 | -39.8% | $91.8K |
| BARCLAYS PLC | NEAR_EXIT | 4,135 | 29 | -99.3% | $223.00 |
| MILLENNIUM MANAGEMENT LLC | TRIM | 242,772 | 132,946 | -45.2% | $1.1M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 61,025 | 19,975 | -67.3% | $164.5K |
| MORGAN STANLEY | NEAR_EXIT | 88,979 | 19,821 | -77.7% | $163.3K |
| UBS Group AG | DOUBLED | 359 | 6,378 | +1676.6% | $52.6K |
| UBS Group AG | NEAR_EXIT | 5,621 | 359 | -93.6% | $3.9K |
| Farther Finance Advisors, LLC | TRIM | 111 | 70 | -36.9% | $770.00 |
| BNP PARIBAS FINANCIAL MARKETS | NEAR_EXIT | 3,104 | 7 | -99.8% | $77.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
4 insiders, 4 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Binder Gwendolyn | Director | AWARD | 6,500 | — | — |
| Jun 11, 2026 | Gibson Neil W | Director | AWARD | 0 | — | — |
| Jun 11, 2026 | Matcham George | Director | AWARD | 6,500 | — | — |
| Jun 11, 2026 | McGaughy R Kent Jr | Director | AWARD | 6,500 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TIL.
Shares short
161,870
Settlement Sep 15, 2026
Change vs prior
+3.2%
Semi-monthly cycle
Days to cover
13.1
At avg daily volume
Of shares outstanding
≈2.4%
Estimate — not % of float
All TIL filing & press-release reports (7)
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 13, 2026
- 8-K reportMay 15, 2026
- PRESS-RELEASE reportMay 15, 2026
- DEFA14A reportApr 24, 2026
- 8-K reportApr 3, 2026
- PRESS-RELEASE reportMar 27, 2026